ACS medicinal chemistry letters · 2026
Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shimokawa Kenichiro, Ono Koji, Asano Moriteru, Hirayama Takaharu, Tokuhara Hidekazu, Tanaka Toshio, Banno Hiroshi, Sakauchi Nobuki, Hirata Yasuhiro, Fujimoto Jun, Kokubo Hironori, Mizojiri Ryo, Cary Douglas R, Ito Masahiro, Maezaki Hironobu, Imaeda Yasuhiro, Tanaka Hiroshi, Uchiyama Noriko, Sameshima Tomoya, Kondo Mitsuyo, Kawamoto Tomohiro, Sugiyama Midori, Yamakawa Hiroko, Morishita Daisuke, Arikawa Yasuyoshi
Аннотация
Cyclin-dependent kinase 12 (CDK12) is a transcription-associated kinase critical in regulating transcription, mRNA splicing, translation, cell cycle progression, and DNA damage repair (DDR) pathways. CDK12 is a notable therapeutic target in cancer owing to its regulation of key DDR genes, including BRCA1 and BRCA2, which are essential in maintaining genomic stability. In this study, we describe the lead optimization of a 1,4-trans-cyclohexane-based series, resulting in the discovery of a novel and highly selective CDK12 inhibitor, CTX-439. CTX-439 demonstrated robust CDK12 inhibition, sustained potency against its homologous protein CDK13, and outstanding selectivity over other CDKs and the broader kinome. A comprehensive in vitro evaluation, including ADME-Tox profiling, identified CTX-439 as a promising drug candidate for targeted cancer therapy.